Molecular Pathobiology of Gastrointestinal Stromal ... - ResearchGate

heinrich.corless.net

Molecular Pathobiology of Gastrointestinal Stromal ... - ResearchGate

Annu. Rev. Pathol. Mech. Dis. 2008.3:557-586. Downloaded from arjournals.annualreviews.org

by Oregon Health & Science University on 02/02/08. For personal use only.

40. Chian R, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, et al. 2001.

Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells

by the D816V c-Kit mutant. Blood 98:1365–73

41. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, et al. 2004. Structural basis

for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem.

279:31655–63

42. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, et al. 2003. Structure of a c-kit product

complex reveals the basis for kinase transactivation. J. Biol. Chem. 278:31461–64

43. Foster R, Griffith R, Ferrao P, Ashman L. 2004. Molecular basis of the constitutive

activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.

J. Mol. Graph. Model. 23:139–52

44. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. 2007. Neoplasia driven by mutant

c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol. Cell

Biol. 27:267–82

45. Liu H, Chen X, Focia PJ, He X. 2007. Structural basis for stem cell factor-KIT signaling

and activation of class III receptor tyrosine kinases. EMBO J. 26:891–901

46. Bauer S, Yu LK, Demetri GD, Fletcher JA. 2006. Heat shock protein 90 inhibition in

imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 66:9153–61

47. Fumo G, Akin C, Metcalfe DD, Neckers L. 2004. 17-Allylamino-17-

demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively

activated KIT protein in human mast cells. Blood 103:1078–84

48. Pauls K, Merkelbach-Bruse S, Thal D, Buttner R, Wardelmann E. 2005. PDGFRα- and

c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive

histological and immunohistochemical features. Histopathology 46:166–75

49. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, et al. 2003. PDGFRA

activating mutations in gastrointestinal stromal tumors. Science 299:708–10

50. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, et al. 2003. Gain-of-function

mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal

tumors. Gastroenterology 125:660–67

51. Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, et al. 2004. Differential

expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of

gastrointestinal stromal tumors depends predominantly on the tumor site. Mod. Pathol.

17:889–94

52. Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, et al. 2005. Correlation of KIT and

platelet-derived growth factor receptor α mutations with gene activation and expression

profiles in gastrointestinal stromal tumors. Oncogene 24:1066–74

53. Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, et al. 2004. PDGFRA

germline mutation in a family with multiple cases of gastrointestinal stromal tumor.

Gastroenterology 126:318–21

54. de Raedt T, Cools J, Debiec-Rychter M, Brems H, Mentens N, et al. 2006. Intestinal

neurofibromatosis is a subtype of familial GIST and results from a dominant activating

mutation in PDGFRA. Gastroenterology 131:1907–12

55. Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB. 2007. The plateletderived

growth factor receptor α is destabilized by geldanamycins in cancer cells. J. Biol.

Chem. 282:445–53

56. Debiec-Rychter M, Wasag B, Stul M, De WI, Van Oosterom A, et al. 2004. Gastrointestinal

stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.

J. Pathol. 202:430–38

580 Corless·Heinrich

More magazines by this user
Similar magazines